Lenvatinib/Pembrolizumab Maintained Beneficial Outcomes When Evaluated by Tumor Size in RCC

Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in advanced renal cell carcinoma in the overall patient population of the phase 3 CLEAR study.

Related Keywords

Germany ,United States ,America ,Lenvatinib Lenvima ,University Hospital Essen ,Interdisciplinary Genitourinary Oncology ,Subgroup Analysis ,Western Europe ,North America ,Immunotherapy In Gu Cancers ,News ,Genitourinary Cancers ,Immuno Oncology ,